|
Lasa M, Notarfranchi L, Agullo C, Gonzalez C, Castro S, Perez JJ, Burgos L, Guerrero C, Calasanz MJ, Flores-Montero J, Oriol A, Bargay J, Rios R, Cabanas V, Cabrera C, Martinez-Martinez R, Encinas C, De Arriba F, Hernandez MT, Palomera L, Orfao A, Martinez-Lopez J, Mateos MV, San-Miguel J, Lahuerta JJ, Rosinol L, Blade J, Cedena MT, Puig N, Paiva B; PETHEMA/GEM Cooperative Group. Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma. J Clin Oncol. 2025 Jan 10;43(2):125-132. doi: 10.1200/JCO.24.00635. Epub 2024 Oct 1. PubMed PMID: 39353166.
AÑO: 2025; IF: 42.1
|
39353166
|
Lakhwani S, Rosinol L, Puig N, Pico-Picos MA, Medina-Gonzalez L, Martinez-Lopez J, Paiva B, Cedena MT, Oriol A, Rios-Tamayo R, Blanchard MJ, Jarque I, Bargay J, Moraleda JM, Carrillo-Cruz E, Sureda A, Krsnik I, Gonzalez E, Casado LF, Marti JM, Encinas C, De Arriba F, Palomera L, Sampol A, Gonzalez-Montes Y, Motllo C, De La Cruz J, Alonso R, Mateos MV, Blade J, Lahuerta JJ, San-Miguel J, Hernandez MT. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection. Haematologica. 2024 Jun 1;109(6):1909-1917. doi: 10.3324/haematol.2023.284154. PubMed PMID: 38031761; PubMed Central PMCID: PMC11141681.
AÑO: 2024; IF: 8.2
|
|
de Arriba de la Fuente F, Gironella Mesa M, Hernandez Garcia MT, Soler Campos JA, Herraez Rodriguez S, Moreno Belmonte MJ, Regueiro Lopez T, Gonzalez-Pardo M, Casanova Espinosa M, On Behalf Of The Carinae Study Investigators. Unravelling Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treatment in Real-World Practice in Spain: The CARINAE Study. Pharmaceuticals (Basel). 2024 Sep 26;17(10):1272. doi: 10.3390/ph17101272. PubMed PMID: 39458913; PubMed Central PMCID: PMC11510635.
AÑO: 2024; IF: 4.3
|
|
Mateos MV, Martinez-Lopez J, Rodriguez Otero P, Gonzalez-Calle V, Gonzalez MS, Oriol A, Gutierrez NC, Rios-Tamayo R, Rosinol L, Alvarez Rivas MA, Bargay J, Gonzalez-Rodriguez AP, Alegre A, Escalante F, Inigo Rodriguez MB, De La Rubia J, Teruel AI, de Arriba F, Palomera L, Hernandez MT, Lopez Jimenez J, Reinoso-Segura M, Garcia Mateo A, Ocio EM, Paiva B, Puig N, Cedena MT, Blade J, Lahuerta JJ, San-Miguel JF; Spanish Myeloma Group (GEM-Pethema). Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance. J Clin Oncol. 2024 Sep 20;42(27):3247-3256. doi: 10.1200/JCO.23.02771. Epub 2024 Jul 22. PubMed PMID: 39038268; PubMed Central PMCID: PMC11404760.
AÑO: 2024; IF: 42.1
|
|
Gonzalez-Calle V, Rodriguez-Otero P, Sureda A, De Arriba F, Reinoso M, Ribas P, Gonzalez-Rodriguez AP, Gonzalez Y, Oriol A, Martinez-Lopez J, Gonzalez MS, Hernandez MT, Sirvent M, Cedena T, Puig N, Paiva B, Blade J, Lahuerta JJ, San-Miguel JF, Mateos MV. Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, nonrandomized, multicenter GEM-SELIBORDARA study. Haematologica. 2024 Jul 1;109(7):2219-2228. doi: 10.3324/haematol.2023.284089. PubMed PMID: 38356463; PubMed Central PMCID: PMC11215366.
AÑO: 2024; IF: 8.2
|